Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB10.16 plus atezolizumab in HPV16-positive advanced or recurrent cervical cancer
2019-002328-33Phase 2Completed
- Sponsor
- Nykode Therapeutics
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VB10.16 and atezolizumab in Cervical Cancer (CC), sponsored by Nykode Therapeutics. Primary endpoint: Incidence and severity of adverse events. Started Sep 2019; status: completed.
02
Drugs
VB10.16atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2019-002328-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002328-33.